Abstract

To replicate, viruses must gain access to the host cell's resources. Interferon (IFN) regulates the actions of a large complement of interferon effector genes (IEGs) that prevent viral replication. The interferon inducible transmembrane protein family members, IFITM1, 2 and 3, are IEGs required for inhibition of influenza A virus, dengue virus, and West Nile virus replication in vitro. Here we report that IFN prevents emergence of viral genomes from the endosomal pathway, and that IFITM3 is both necessary and sufficient for this function. Notably, viral pseudoparticles were inhibited from transferring their contents into the host cell cytosol by IFN, and IFITM3 was required and sufficient for this action. We further demonstrate that IFN expands Rab7 and LAMP1-containing structures, and that IFITM3 overexpression is sufficient for this phenotype. Moreover, IFITM3 partially resides in late endosomal and lysosomal structures, placing it in the path of invading viruses. Collectively our data are consistent with the prediction that viruses that fuse in the late endosomes or lysosomes are vulnerable to IFITM3's actions, while viruses that enter at the cell surface or in the early endosomes may avoid inhibition. Multiple viruses enter host cells through the late endocytic pathway, and many of these invaders are attenuated by IFN. Therefore these findings are likely to have significance for the intrinsic immune system's neutralization of a diverse array of threats.

Highlights

  • The 2009 H1N1 pandemic provided a strong reminder of the threat that influenza A virus poses to world health

  • We report several novel findings regarding the antiviral actions of IFN and the transmembrane interferon effector genes (IEGs), IFITM3

  • This study demonstrates that IFN inhibits the nuclear translocation of viral ribonucleoproteins (vRNPs), and that IFITM3 is required for this IFN-mediated block, with both endogenous and overexpressed IFITM3 inhibiting vRNP nuclear entry

Read more

Summary

Introduction

The 2009 H1N1 pandemic provided a strong reminder of the threat that influenza A virus poses to world health (http://www. cdc.gov/h1n1flu/cdcresponse.htm). The 2009 H1N1 pandemic provided a strong reminder of the threat that influenza A virus poses to world health The most effective means of protection against influenza is the seasonal vaccine. If the vaccine does not match the viral strains, its effectiveness can be reduced to 50% or less [1,2]. Only two approved influenza drugs remain effective, zanamivir (Relenza) and oseltamivir (Tamiflu). Resistance to zanamivir is rare, there has been an increase in oseltamivir-resistant flu strains [3]. Of concern, both drugs target viral neuraminidase (NA), precluding combinatorial therapy to minimize resistance [4,5]. Research to identify new anti-influenza strategies would be useful

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.